CCL2 and lung carcinoma: C1D1 MDSC from patients with clinical benefit had significantly higher expression of MALAT1, which has been shown to be negatively correlated with the proportion of MDSC in lung cancer, several antigen presentation genes (HLA-DPA1, HLA-DRA, HLA-DPB1, HLA-DRB1); GNLY, an inducer of monocytic differentiation; and the chemokine CCL2 than patients with PD (Figure 5H) (27–29).